Abstract Objectives: Our aim was to describe patient characteristics and trends in the use of extracorporeal membrane oxygenation (ECMO) for the treatment of acute respiratory distress syndrome (ARDS) in the United States from 2006 to 2011. Methods: We used the Nationwide Inpatient Sample to isolate all patients aged 18 years who had a discharge International Classification of Diseases, Ninth Revision diagnosis of ARDS, with and without procedure codes for ECMO, between 2006 and 2011. Results: We examined a total of 47 911 414 hospital discharges, representing 235 911 271 hospitalizations using national weights. Of the 1 479 022 patients meeting the definition of ARDS (representing 7 281 206 discharges), 775 underwent ECMO. There was a 409% relative increase in the use of ECMO for ARDS in the United States between 2006 and 2011, from 0.0178% to 0.090% (P ¼ .0041). Patients treated with ECMO had higher in-hospital mortality (58.6% vs 25.1%, P < .0001) and longer hospital stays (15.8 days vs 6.9 days, P < .0001). They were also younger (47.9 vs 66.4 years, P < .0001) and more likely to be male (62.2% vs 49.6%, P < .0001). The median time to initiate ECMO from the time of admission was 0.5 days (interquartile range [IQR] 4.9 days). Conclusion: There has been a dramatic increase in ECMO use for the treatment of ARDS in the United States.
Introduction
Acute respiratory distress syndrome (ARDS) is a state of diffuse inflammatory lung injury characterized by acute-onset, noncardiogenic pulmonary edema with hypoxemia as defined by an arterial partial pressure of oxygen to inspired oxygen ratio of under 300. 1 Despite significant advances in intensive care, mortality from ARDS remains high. [2] [3] [4] [5] [6] To date, the only interventions that have been shown to improve survival in ARDS are low tidal volume ventilation, prone positioning, and neuromuscular blockade. [7] [8] [9] The use of extracorporeal membrane oxygenation (ECMO) for the treatment of ARDS has received significant attention in the past decade. The ECMO provides oxygenation without the need for mechanical ventilation, avoiding further lung injury. The 2014 Extracorporeal Life Support Organization (ELSO) guidelines suggest considering ECMO for patients with highrisk hypoxic or hypercarbic respiratory failure, despite optimal conventional ventilation. 10 Furthermore, a recent Cochrane review concluded that ECMO remains a rescue therapy for patients with acute respiratory failure, citing inconclusive and heterogenous evidence and noting rapidly changing technology and practice patterns.
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The 2012 ELSO registry report indicates increased use of ECMO for all-cause respiratory failure after the 2009 H1N1 influenza pandemic but does not identify patient characteristics associated with ECMO use or focus on ARDS specifically. 12 The goal of our study was to examine patterns of ECMO use for the treatment of ARDS in the United States between 2006 and 2011.
Materials and Methods
We report our study according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. 13 A waiver of consent was obtained from the University of British Columbia Clinical Research Ethics Board (H15-01943).
Study Population
Data from the Nationwide Inpatient Sample (NIS) were examined for the years 2006 to 2011. The NIS is a nationally representative data set that captures approximately 20% of all United States hospital discharges. It is a complex survey designed to accurately calculate national estimations of the entire population, released by the Agency for Healthcare Research and Quality (AHRQ).
We isolated all patients who were older than 18 years of age and had a discharge diagnosis of ARDS. Our definition of ARDS was consistent with previous authors and included (1) International Classification of Diseases, Ninth Revision (ICD-9) codes for acute respiratory failure following trauma and surgery (518.51); (2) other pulmonary insufficiency, not elsewhere classified, following trauma and surgery (518.52); (3) acute and chronic respiratory failure following trauma and surgery (518.53); (4) acute respiratory failure (518.81); (5) and other pulmonary insufficiency, not elsewhere classified (518.82). 14 We then isolated patients who had ICD-9 procedure codes for ECMO (39.65 and 37.62) from the overall ARDS group (Figure 1) . We also identified patients who received inhaled nitric oxide (00.12) and renal replacement therapy (39.95 and 38.95).
Patient-level factors included age, sex, race (white, black, Hispanic, other, or missing), length of stay, inhospital mortality, insurance status (coverage vs no coverage), and income quartile of the ZIP code. Hospital characteristics included teaching status (teaching vs nonteaching), size (as defined by the AHRQ), and region of the country (Northeast, Midwest, South, and West).
Statistical Analysis
Data were analyzed using complex survey procedures in SAS version 9.4 (SAS Institute, Cary, North Carolina); national estimates were obtained with appropriate national weights. Chi-square tests were used for nominal or ordinal outcomes, and independent t tests were used for continuous data. Trend analysis was performed using linear regression. All tests were performed at an a level of .05.
Results
We analyzed a total of 47 911 414 hospital discharges, representing 235 911 271 hospitalizations using appropriate national weights. Of the 1 479 022 discharges that met the definition of ARDS, representing 7 281 206 discharges, 775 patients underwent ECMO (Table 1) . Patients treated with ECMO had higher mortality (58.6% vs 25.1%, P < .0001) and longer hospital stays (15.8 days, interquartile range [IQR] 28.5 vs 6.9, IQR 10.3, P < .0001). They were also younger (47.9 years, standard deviation [SD] 16.8 vs 66.4, SD 16.9, P < .0001), more likely to be male (62.2% vs 49.6%, P < .0001), and more likely to receive inhaled nitric oxide (2.4% vs 0.02%, P < .0001). Hospital characteristics associated with the use of ECMO included teaching status (92.0% vs 45.6%, P ¼ <.0001) and large hospital size (86.7% vs 64.9%, P ¼ <.0001). The effects of region of the country (P ¼ .11) and of income quartile by ZIP code were not significant (P ¼ .10).
There was a 409% relative increase in the use of ECMO for ARDS in the United States between 2006 and 2011, from 0.0177% to 0.0901% (P ¼ .0041; Figure 2 ). There was no change in the ECMO case mortality during the study period (Figure 3 , P ¼ .14). The case mortality rate for ARDS decreased significantly from 28.4% to 22.4% during the study period (Figure 4 , P ¼ <.01).
Discussion
There has been a dramatic increase in ECMO use for the treatment of ARDS in the United States. Patients who receive ECMO tend to be young males, to have higher in-hospital mortality, and to be treated in large teaching hospitals.
Our observed increase in ECMO is consistent with ELSO registry data. 12 One explanation for this increase is the successful use of ECMO for severe cases of ARDS during the H1N1 influenza epidemic. The ensuing attention in the literature, as well as the publication of the CESAR trial, may have prompted more clinicians to consider this therapy in cases of acute respiratory failure. [15] [16] [17] [18] [19] [20] [21] Furthermore, refinements in ECMO technology since its inception allow for easier, safer, and wider use. 22 Our finding that young males are more likely to receive ECMO is consistent with models proposed to estimate the probability of survival in patients who underwent ECMO, which show that both younger age and male gender are associated with improved survival. 23, 24 That patients who receive ECMO are more likely to be treated in tertiary academic hospitals is unsurprising, given the resource-intensive, highly specialized nature of the therapy.
In our study, the 59% mortality rate in patients who underwent ECMO is consistent with the latest ELSO registry paper, which showed a 51% mortality rate in adult patients undergoing veno-venous ECMO for ARDS. 12 Other publications of heterogeneous study populations have reported a wide range of mortality in ECMO-treated patients with ARDS, from 16% to 64%. 20 The finding that patients who underwent ECMO have a higher mortality rate than the control group may reflect that sicker patients receive ECMO as a rescue measure.
The role of ECMO for ARDS remains controversial. 25, 26 Several recent meta-analyses cite few well-designed randomized controlled trials, particularly in the current era of lungprotective ventilation. 11, 20 Significant advances in ECMO equipment and techniques over the past decade also make interpretation of historical data difficult. 22, 27 The CESAR trial may support transfer to an ECMO-capable center for patients with severe ARDS, but results should be interpreted with caution. given the lack of standardized therapy in the control group and differences in rates of lung-protective ventilation. 21 Studies are underway that will hopefully provide more definitive answers about the role of ECMO and extracorporeal CO 2 removal in treating ARDS. 17, 28 The strength of our study lies in the use of a large, nationwide data set capturing 20% of all hospital admissions. This allows for excellent generalizability and accurate representation of the use of ECMO for ARDS in the United States.
The results of our study need to be interpreted in the context of the study design. Retrospective observational studies based on discharge data are susceptible to patient selection bias and the possibility of coding errors. Furthermore, we could not discern the specific etiologies of ARDS, which may influence its outcomes.
Conclusion
The use of ECMO for the treatment of ARDS in the United States increased by over 400% between 2006 and 2012. Patients who receive ECMO are tend to be younger, to be male, and to be treated in large tertiary care hospitals. Mortality for the ECMO-treated group was 59%. Further research is needed to clarify the role of ECMO in treating ARDS.
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